UK clinical trial regs are changing — here’s what’s happening

Change is coming to the UK’s clinical trials landscape – and it’s big. From 28 April 2026, updated Clinical Trial Regulations will come into play, representing the biggest shift in how we plan and deliver clinical trials in the UK in almost two decades.

The amendments, presented by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA), were co-created in partnership with patients, researchers, and industry representatives, and represent a new era in UK clinical research.

The amendments bring the regulations into alignment with current culture. By promoting transparency and clarifying expectations, they aim to enhance participant safety, increase trial diversity, reduce researcher burden, speed up approvals, and position the UK as a trusted global research leader.

Here, we highlight some of the key updates and what they could mean in practice.

1. Updates to language and definitions

One of the most noticeable updates is the modernisation of terminology:

• Definitions have been updated to align with current language and tone:
  
  • ‘Subject’ is now ‘participant’
  • ‘Trial site’ is now ‘trial location’
  • ‘Amendment’ is now ‘modification’‍
• There are now three distinct categories of trial modification:
  
  • Substantial modifications
  • Modification of an important detail
  • Minor modifications
• The definition of Chief Investigator (CI) has been updated to refer to a ‘healthcare professional’. This change means a wider range of registered clinical professions are eligible to act as CIs. Individuals are required to be appropriately qualified through education, training, and experience.

2. Integrated statutory review

Combined Review (MHRA and a Research Ethics Committee) is a system that allows researchers to apply for ethics and regulatory approval at the same time. It has worked in practice for years, but now it’s embedded in the regulations. This means:

• A single integrated submission rather than separate parallel processes
• Faster, clearer decisions and improved communication between stakeholders
• Defined timelines and expectations for regulators and sponsors

For trial teams, this simplifies planning, reduces rework, and supports better alignment between regulatory and ethics considerations.

Initial applications will be made using IRAS. Learn more about the process and whether you need to create an account here.

3. Transparency is now a legal requirement

For the first time, the UK has statutory transparency obligations for all clinical trials of investigational medicinal products (CTIMPs):

• Trials must be publicly registered in a recognised registry
• Results summaries must be published within 12 months
• Plain-language summaries should be offered to participants

This is no longer optional best practice, but law. Trial teams should create standard operating procedures (SOPs) for trial registration, result sharing, and the process of developing timely participant-ready communications.

4. Expectations for trial start and oversight

The updated regulations introduce clearer expectations around when trials should begin and how they should be overseen once approved.

• Trial approvals will no longer remain valid indefinitely. Sponsors are expected to recruit the first UK participant within two years of approval, unless extended
• There is a clearer emphasis on risk-proportionate oversight, meaning the level of monitoring and governance should reflect the level of risk posed by the trial
• Regulatory expectations are more explicitly aligned with international Good Clinical Practice (GCP) principles

For trial teams, this means planning for faster trial start-up and ensuring oversight arrangements are proportionate to the risks involved.

Things to start thinking about

With April just around the corner, you may want to:

• Update your SOPs, playbooks, and templates to reflect the new terminology and processes
• Train your teams on the regulatory changes and what’s expected operationally
• Make sure your quality checks and oversight processes cover the new transparency and trial start rules
• Plan trial registrations and results reporting processes ahead of time

These changes don’t rewrite the basics of ethical, well-run trials, but they do clearly define expectations and bring the UK closer to global standards.

Don’t forget — on the same day as these updated regulations, the latest GCP Guidelines will also take effect in the UK. All clinical trials should comply with the principles of GCP.

If you or your team would like a short briefing slide deck or a practical checklist based on these changes, drop us a line — we are happy to help.

‍